期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Gastric cancer:The times they are a-changin' 被引量:6
1
作者 Maria Antonietta Satolli Lucio Buffoni +1 位作者 Rosella Spadi Ilaria Roato 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2015年第11期303-316,共14页
Gastric cancer is the third leading cause of cancer death worldwide.Even though during these last decades gastric cancer incidence decreased in Western countries,it remains endemic and with a high incidence in Eastern... Gastric cancer is the third leading cause of cancer death worldwide.Even though during these last decades gastric cancer incidence decreased in Western countries,it remains endemic and with a high incidence in Eastern countries.The survival in advanced and metastatic stage of gastric cancer is still very poor.Recently the Cancer Genoma Atlas Research Network identified four subtypes with different molecular profiles to classify gastric cancer in order to offer the optimal targeted therapies for pre-selected patients.Indeed,the key point is still the selection of patients for the right treatment,on basis of molecular tumor characterization.Since chemotherapy reached a plateau of efficacy for gastric cancer,the combination between cytotoxic therapy and biological agents gets a better prognosis and decreases chemotherapeutic toxicity.Currently,Trastuzumab in combination with platinum and fluorouracil is the only approved targeted therapy in the first line for c-erb B2 positive patients,whereas Ramucirumab is the only approved targeted agent for patients with metastatic gastric cancer.New perspectives for an effective treatment derived from the immunotherapeutic strategies.Here,we report an overview on gastric cancer treatments,with particular attention to recent advances in targeted therapies and in immunotherapeutic approach. 展开更多
关键词 TARGETED therapy CHEMOTHERAPY GASTRIC cancer Immun
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部